Akebia Therapeutics (AKBA) Gross Margin (2018 - 2026)

Akebia Therapeutics (AKBA) has 9 years of Gross Margin data on file, last reported at 77.05% in Q1 2026.

• On a quarterly basis, Gross Margin fell 965.0% year-over-year to 77.05% in Q1 2026; TTM through Mar 2026 was 81.01%, a 328.0% increase from a year earlier, with the FY2025 full-year figure at 83.29%, up 23.0% from the prior year.
• Gross Margin for Q1 2026 stood at 77.05%, down from 78.25% in the prior quarter.
• Over the last five years, Gross Margin for AKBA reached as high as 86.7% in Q1 2025 and fell as low as 30301.32% in Q1 2022.
• Historically, Gross Margin has averaged 1715.19% across 5 years, with a median of 75.58% in 2024.
• Across the five-year window, Gross Margin sank 3035238 bps in 2022 and surged 3037337 bps in 2023, its largest moves.
• Year by year, Gross Margin stood at 57.69% in 2022, then jumped by 44 bps to 82.82% in 2023, then dropped by 9 bps to 75.58% in 2024, then rose by 4 bps to 78.25% in 2025, then declined by 2 bps to 77.05% in 2026.
• Per Business Quant data, the three most recent Gross Margin figures were 77.05% in Q1 2026, 78.25% in Q4 2025, and 84.03% in Q3 2025.